Page 9 - எடுப்போசை சுவாச News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) MONTREAL, QC / ACCESSWIRE / December 22, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England. The new strain appears to be more easily transmissible due to a mutation in the Spike Protein, the crown-like structure on the surface of the virus which allows it to gain entry into the host cell. Sunshine Biopharma s Anti-Coronavirus compound, SBFM-PL4, acts on the Coronavirus Papain-Like Protease (PLpro) which is a non-structural protein encoded by the viral genome and synthesized by the hijacked protein synthesis machinery of the host cell. Sunshine Biopharma s SBFM-PL4 inhibits PLpro and arrests viral replication. SBFM-PL4 is expected to inhibit the PLpro of the UK variant just as well as it does the original strain si

United kingdomKostenloser wertpapierhandelSteven slilatyCamille sebaalyExchange commissionSunshine biopharma incMcgill university jewishSunshine biopharmaSpike proteinCoronavirus papain like proteaseAcute respiratoryMultidrug resistant cancer cellsPancreatic cancerSmall cell lung cancerBreast cancerUterine sarcoma